Medical disclaimer: This article is for general informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Testosterone replacement therapy is a prescription treatment requiring clinical evaluation and ongoing medical supervision. Consult a licensed physician before making any decisions about hormone therapy.
Testosterone replacement therapy has moved from the margins of men’s medicine to one of the most discussed topics in preventive health — and with good reason. Low testosterone affects an estimated 2–6 million men in the United States, and that number climbs steadily with age. Yet despite the growing conversation around TRT, reliable, comprehensive information remains scattered across clinical guidelines, forum posts, and marketing copy that’s difficult to distinguish from one another.
This guide covers everything you need to understand TRT as a medical treatment: what it is, who it’s for, how it works, what the delivery options are, what monitoring looks like, what it costs, and what the evidence actually says about benefits and risks. It’s written for men who want to understand their options, not be sold to.
1. What Is Testosterone Replacement Therapy?
Testosterone replacement therapy (TRT) is a medically supervised treatment that restores testosterone to healthy physiological levels in men whose bodies produce inadequate amounts. It is prescribed specifically for hypogonadism — a clinical condition defined by low testosterone combined with symptoms that impair quality of life.
TRT is not a performance-enhancing drug protocol. It is hormone replacement, analogous to thyroid hormone treatment for hypothyroidism or insulin therapy for diabetes. The goal is to restore levels within a normal physiological range — not to push them above what the body would naturally produce at peak.
Primary vs. Secondary Hypogonadism
Primary hypogonadism originates in the testes themselves, which have been damaged or are not functioning normally. Causes include Klinefelter syndrome, orchitis, cancer treatment, and testicular injury.
Secondary hypogonadism originates in the brain — specifically in the hypothalamus or pituitary gland, which fail to send the hormonal signals that tell the testes to produce testosterone. Causes include obesity, pituitary tumors, chronic illness, opioid use, and the natural age-related decline in hypothalamic-pituitary function.
Both forms are treatable with TRT. The distinction matters because secondary hypogonadism may in some cases respond to lifestyle changes (particularly significant weight loss in obese men), while primary hypogonadism typically requires ongoing replacement therapy.
2. What Does Testosterone Do in the Adult Body?
Testosterone is the primary male sex hormone, produced mainly in the testes under the direction of the hypothalamic-pituitary-gonadal (HPG) axis. In adult men, it influences virtually every major physiological system.
What testosterone regulates in the adult male body
💪 Muscle and metabolism Stimulates protein synthesis, supports lean mass, regulates fat distribution and metabolic rate
🦴 Bone density Maintains bone mineral density through direct androgen receptor signaling and estradiol conversion
🧠 Cognitive function and mood Androgen receptors in the brain affect motivation, memory, concentration, and emotional regulation
❤️ Cardiovascular health Influences red blood cell production, lipid metabolism, vascular tone, and cardiac muscle function
🔋 Energy and fatigue Affects mitochondrial function, sleep architecture, and overall physical energy baseline
🔵 Sexual function Drives libido, influences erectile function through nitric oxide pathways and central arousal signaling
Fig. 1 — Primary physiological roles of testosterone in adult men. Based on peer-reviewed research on hypogonadal and eugonadal populations.
After the mid-30s, testosterone production declines at an average rate of 1–2% per year. For most men, this gradual decline produces minimal symptoms. For those whose levels fall below clinical thresholds — or who are more sensitive to androgen decline — the functional effects become significant.
3. Signs and Symptoms of Low Testosterone
Low testosterone rarely presents as a single obvious symptom. More typically, it produces a cluster of changes that develop gradually over months or years — often attributed to stress, aging, or lifestyle before a hormonal cause is considered.
Physical symptoms
Reduced muscle mass and strength, with a diminished response to resistance training
Increased body fat, particularly around the abdomen, even without dietary changes
Persistent physical fatigue that adequate sleep does not resolve
Reduced exercise tolerance and slower recovery
Decreased body and facial hair
Reduced morning erections or erectile quality
Decreased testicular size (in primary hypogonadism)
Hot flashes (less common; more associated with acute testosterone loss)
Psychological and cognitive symptoms
Low libido — reduced sexual desire rather than purely mechanical erectile difficulties
Depressed mood, irritability, or emotional flatness
Reduced motivation and drive
Difficulty concentrating or memory lapses
Reduced sense of well-being that doesn’t respond to lifestyle changes
These symptoms overlap significantly with depression, thyroid dysfunction, sleep apnea, and normal aging. This is precisely why symptom recognition should prompt lab testing rather than treatment — the symptoms alone don’t confirm a diagnosis. For a detailed breakdown of how these symptoms cluster and what they may signal, see the overview of fatigue, irritability, and low libido in men over 50.
Diagnosis requires both laboratory confirmation and clinical symptoms. A single low testosterone reading is not sufficient — current guidelines from the American Urological Association and the Endocrine Society require two separate morning testosterone measurements below the reference range before initiating treatment.
Why morning testing matters
Testosterone follows a circadian rhythm, peaking in the early morning (7–10 AM) and declining throughout the day. Afternoon or evening measurements can read 20–30% lower than morning levels in healthy men. Testing outside the morning window produces artificially low results and can lead to misdiagnosis.
Key lab markers in a diagnostic workup
Standard lab panel for low testosterone evaluation
Essential Total testosterone Drawn twice on separate mornings; below 300 ng/dL generally considered deficient
Essential Free testosterone Accounts for SHBG binding; some men with normal total T have low free T
Important LH and FSH Pituitary hormones; determine if hypogonadism is primary or secondary
Important Prolactin Elevated prolactin suppresses testosterone; may indicate pituitary tumor
Important Estradiol (E2) Testosterone-to-estrogen ratio affects symptoms and guides monitoring
Baseline CBC, PSA, metabolic panel, thyroid Rule out other causes; establish pre-treatment baseline for monitoring
Fig. 2 — Standard diagnostic lab panel. Ordered by a physician based on clinical presentation; not all markers required in every case.
A low testosterone level in a man without symptoms does not automatically indicate treatment. Current guidelines recommend against treating asymptomatic men with borderline levels — the decision to treat is based on the combination of confirmed biochemical deficiency and clinically meaningful symptoms.
5. Who Is a Candidate for TRT?
The ideal candidate for TRT is an adult man with both confirmed biochemical hypogonadism (two low morning testosterone readings) and symptoms that are meaningfully affecting quality of life. Additional clinical considerations include:
No untreated obstructive sleep apnea (OSA can suppress testosterone and should be treated first)
No active prostate cancer or breast cancer
Hematocrit below 50% at baseline
No plans for fatherhood in the near term (TRT suppresses sperm production — see fertility section in FAQ)
Willingness to commit to ongoing lab monitoring
Men with obesity and low testosterone should discuss the potential for lifestyle-driven testosterone recovery with a physician before initiating TRT. Significant weight loss in obese men has been shown to raise testosterone levels substantially in some cases. However, for men with confirmed primary hypogonadism or those whose levels remain deficient despite lifestyle improvement, TRT is the appropriate intervention.
Testosterone can be delivered through several routes. Each has different pharmacokinetic profiles, administration requirements, cost structures, and tolerability characteristics. The choice is made in collaboration with a physician based on clinical goals, lifestyle, and patient preference.
Method
Frequency
Level stability
Approx. cost/mo
Key considerations
Injection (cypionate / enanthate)
Weekly or every 2 weeks
Good (weekly)
$20–$60
Most cost-effective. Self-injectable. Peaks and troughs with E2W dosing; weekly reduces fluctuation.
Topical gel / cream
Daily
Excellent
$100–$400
Steady daily levels. Skin-to-skin transfer risk. Absorption varies by individual.
Subcutaneous pellets (Testopel)
Every 3–6 months
Very good
$400–$1,500 per insertion
No daily administration. In-office procedure. Cannot adjust dose once inserted. See: pellets vs injections guide.
Transdermal patch
Daily
Moderate
$200–$500
No injection required. Skin irritation common. Higher cost than injections for similar efficacy.
Oral testosterone (Jatenzo, Kyzatrex)
Twice daily
Moderate
$400–$600
FDA-approved. No injection. Must be taken with fat-containing meal. Limited insurance coverage.
Table 1 — TRT delivery method comparison. Cost ranges are general U.S. market estimates as of 2026. See the full TRT cost breakdown for detailed pricing by delivery method and care model.
7. Benefits of TRT: What the Research Shows
The evidence base for TRT in men with confirmed hypogonadism is substantial and growing. The landmark TRAVERSE trial (2023) — the largest randomized controlled trial of testosterone therapy to date, enrolling over 5,200 men with hypogonadism and elevated cardiovascular risk — provided the most rigorous safety and efficacy data available.
Body composition
Multiple controlled studies demonstrate that TRT in hypogonadal men reduces fat mass and increases lean muscle mass. The TRAVERSE trial showed significant improvements in body composition compared to placebo. Effects are most pronounced in men with low baseline testosterone and become apparent within 3–6 months.
Sexual function and libido
Improvement in libido is one of the most consistently documented benefits of TRT in hypogonadal men. Erectile function improvements are more variable — TRT addresses the hormonal component, but vascular contributors to ED require separate evaluation. For men whose ED has a significant hormonal component, see the overview of erectile dysfunction and hormones.
Bone density
TRT consistently increases bone mineral density in hypogonadal men over 12–24 months, particularly at the lumbar spine and femoral neck. This is clinically relevant for men with longstanding deficiency, who may have already experienced measurable bone density loss.
Mood and quality of life
Multiple randomized trials show improvements in mood, energy, and quality-of-life scores in hypogonadal men treated with TRT. The effect size varies — men with more severe deficiency and more pronounced psychological symptoms tend to see larger improvements.
Metabolic markers
TRT improves insulin sensitivity, reduces visceral fat, and modestly improves lipid profiles in hypogonadal men with metabolic dysfunction. This is particularly relevant for men with type 2 diabetes or pre-diabetes alongside low testosterone.
Cardiovascular outcomes
This has been the most debated area of TRT research. The TRAVERSE trial provided reassuring data: testosterone therapy did not significantly increase the risk of major adverse cardiovascular events (MACE) compared to placebo in men with hypogonadism and elevated cardiovascular risk. The trial did identify increased rates of atrial fibrillation and pulmonary embolism in the testosterone group — findings that inform monitoring protocols but do not contraindicate TRT in appropriately selected patients. For context on how testosterone levels relate to longer-term health outcomes, see the analysis of baseline testosterone and mortality risk.
8. Risks and Side Effects of TRT
TRT, like any hormonal intervention, carries risks. Most are manageable with proper monitoring and dose adjustment. Understanding them upfront is part of making an informed decision. The full overview of TRT side effects covers each in clinical detail.
Common TRT side effects and how they’re managed
Monitor closely Elevated hematocrit (polycythemia) TRT raises red blood cell production. Hematocrit above 54% requires dose adjustment or therapeutic phlebotomy. See: high hematocrit on TRT.
Monitor closely Elevated estradiol Testosterone converts to estradiol via aromatase. Elevated E2 can cause water retention, mood changes, and gynecomastia. Managed with dose adjustment or aromatase inhibitors if needed.
Expect and manage Testicular atrophy and fertility suppression Exogenous testosterone suppresses LH and FSH, reducing testicular function and sperm production. hCG can preserve function for men concerned about fertility. Generally reversible upon discontinuation.
Usually mild Acne and oily skin Androgenic effect on sebaceous glands. More common in younger men and those with higher doses. Usually manageable with skin hygiene; severe cases may require dose reduction.
Usually mild Sleep apnea worsening TRT may worsen existing OSA. Men with undiagnosed or undertreated sleep apnea should be evaluated before starting therapy.
Contraindication Prostate health TRT is contraindicated in active prostate cancer. PSA monitoring is standard practice. Current evidence does not support TRT causing prostate cancer in healthy men, but monitoring is maintained throughout treatment.
Fig. 3 — Common TRT side effects and management approaches. This is a general overview; individual risk profiles require physician evaluation.
9. Lab Monitoring on TRT
Ongoing monitoring is not optional with TRT — it is what separates a well-managed protocol from an unmanaged one. Standard monitoring follows Endocrine Society and AUA guidelines.
Monitoring schedule
3 months after starting: Total testosterone, free testosterone, hematocrit, PSA, estradiol
6 months: Full panel including metabolic markers and lipids
Every 6–12 months once stable: Ongoing hormone levels, hematocrit, PSA
Annually: DRE (digital rectal exam) in men over 40; bone density in men with confirmed deficiency or osteoporosis risk
Labs are timed based on the delivery method — for injectable testosterone, blood is typically drawn just before the next dose (trough) or at midpoint, depending on what the physician wants to assess. This matters because a peak draw after injection will show much higher levels than the trough, and the reported number needs context to be interpreted correctly.
10. How Much Does TRT Cost?
TRT costs vary significantly by delivery method, insurance status, and care model. Injectable testosterone cypionate is the most cost-effective option — with insurance and a confirmed hypogonadism diagnosis, monthly medication costs can be as low as $10–$30. Without insurance, total annual cost for a monitored injectable protocol typically ranges from $1,500–$4,000 including labs and physician fees.
For a complete breakdown by delivery method, insurance vs. out-of-pocket, and traditional vs. online clinic models, see the dedicated TRT cost guide.
11. TRT vs. Natural Testosterone Support
For men with confirmed clinical hypogonadism, lifestyle interventions alone are generally insufficient to restore testosterone to therapeutic levels. However, for men with borderline or low-normal levels, several evidence-based lifestyle factors meaningfully support testosterone production:
Resistance training: Consistently associated with higher testosterone in men of all ages
Sleep quantity and quality: Testosterone is primarily produced during sleep; chronic sleep restriction suppresses levels significantly
Weight management: Visceral fat drives aromatase activity (converting testosterone to estrogen); significant weight loss raises testosterone in obese men
Stress reduction: Chronic cortisol elevation suppresses the HPG axis
Vitamin D and zinc: Both involved in testosterone synthesis; deficiency is associated with lower levels in some populations
These are adjuncts, not alternatives to TRT in confirmed deficiency. They’re relevant to men who are monitoring borderline levels and want to optimize before deciding whether to treat, and to men on TRT who want to support their overall hormonal health.
12. What to Expect Month by Month on TRT
Typical TRT response timeline — general ranges, individual results vary
Weeks 1–4 Early changes: Improved libido often first. Some men notice better energy and mood. Morning erections may increase. Sleep may improve.
Months 2–3 Physical changes begin: Increased strength and endurance. Body fat starts shifting. First lab check at 3 months for dose titration.
Months 3–6 Meaningful body composition changes: Lean mass increases become visible. Visceral fat continues to decline. Mood stabilizes. Protocol typically finalized.
Months 6–12 Full metabolic response: Lipid profiles and insulin sensitivity improvements measurable on labs. Continued body composition progress with training.
12–24 months Bone density: Measurable increases in bone mineral density on DEXA for men with confirmed deficiency. Longest-latency benefit.
Fig. 4 — General response timeline for TRT in confirmed hypogonadism. Timelines vary significantly based on severity of deficiency, baseline health, dose, and individual response. Not a guarantee of outcomes.
FAQ
Will TRT affect my fertility?
Yes — exogenous testosterone suppresses the pituitary signals (LH and FSH) that drive sperm production. Most men on standard TRT experience significant reductions in sperm count. For men who wish to preserve fertility, human chorionic gonadotropin (hCG) is sometimes prescribed alongside TRT to maintain testicular function, or alternative approaches (clomiphene, anastrozole) may be used to stimulate natural testosterone production without suppressing fertility. This requires direct discussion with a physician before starting any protocol.
Does TRT cause prostate cancer?
Current evidence does not support the hypothesis that TRT causes prostate cancer in men without pre-existing prostate cancer. The “androgen hypothesis” — that high testosterone drives prostate cancer — has not been borne out in randomized trial data. However, TRT is contraindicated in men with active prostate cancer, and PSA monitoring throughout treatment is standard practice. Men with elevated PSA at baseline undergo additional evaluation before TRT is initiated.
Is TRT for life once you start?
For men with primary hypogonadism, long-term therapy is typically required. For men with secondary hypogonadism — where the problem is in the HPG axis signaling rather than the testes themselves — the picture is more nuanced. Some men discontinue TRT after significant lifestyle changes and maintain adequate levels naturally. Discontinuation should be medically supervised, with a plan for monitoring the recovery of natural testosterone production.
Can TRT cause heart problems?
The TRAVERSE trial (2023), the largest RCT of TRT in hypogonadal men, found no significant increase in major adverse cardiovascular events compared to placebo. The trial did find increased rates of atrial fibrillation and pulmonary embolism in the testosterone group. Men with pre-existing cardiovascular conditions receive additional evaluation and more frequent monitoring. TRT is not considered contraindicated in most men with cardiovascular disease, but the decision requires individualized risk assessment.
How long does TRT take to work?
Libido improvements are often among the first changes men notice, within 3–4 weeks. Physical changes (body composition, strength, energy) typically become apparent between 2–6 months. The full metabolic response — lipid improvements, insulin sensitivity, continued body composition change — develops over 6–12 months. Bone density improvements take 12–24 months to register on imaging. Individual timelines vary based on deficiency severity, dose, and baseline health.
What happens if I stop TRT?
When TRT is discontinued, the body’s natural testosterone production — which is suppressed during treatment — gradually recovers. Recovery timelines vary from weeks to months depending on the duration of TRT and individual physiology. During recovery, some men use SERMs (clomiphene, enclomiphene) to stimulate the HPG axis. Symptoms of low testosterone typically return during the recovery period. Discontinuation should be planned with a physician.
Can I drink alcohol on TRT?
Moderate alcohol consumption is not contraindicated on TRT, but chronic heavy drinking suppresses testosterone production independently and increases aromatase activity (which converts testosterone to estrogen). Men on TRT who drink heavily may see reduced treatment efficacy and elevated estradiol. The general guidance is consistent with what would be recommended for overall health: moderation.
Is TRT the same as anabolic steroid use?
No. TRT aims to restore testosterone to a physiological range — levels that a healthy man would naturally produce. Anabolic steroid use involves supraphysiological doses that push levels far beyond the normal range, typically for performance or physique goals rather than medical need. The risk profiles differ significantly, as do the clinical oversight, monitoring protocols, and legal status. TRT prescribed by a physician for confirmed hypogonadism is a legal, medically supervised treatment. Non-prescribed supraphysiological testosterone use is not.
References
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229
Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE Trial). N Engl J Med. 2023;389(2):107–117. doi:10.1056/NEJMoa2215025
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423–432. doi:10.1016/j.juro.2018.03.115
Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol. 2017;72(6):1000–1011. doi:10.1016/j.eururo.2017.03.032
Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611–624. doi:10.1056/NEJMoa1506119
Khera M, Broderick GA, Carson CC, et al. Adult-onset hypogonadism. Mayo Clin Proc. 2016;91(7):908–926. doi:10.1016/j.mayocp.2016.04.022
Wu FC, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010;363(2):123–135. doi:10.1056/NEJMoa0911101
